Log In
BCIQ
Print this Print this
 

SRP-4045

  Manage Alerts
Collapse Summary General Information
Company Sarepta Therapeutics Inc.
DescriptionPhosphorodiamidate morpholino oligomer (PMO) targeting exon 45
Molecular Target DNA
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase III
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD); Treat Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today